Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

NorwayBack to Norway

Clinical trials in Stavanger – page 9

131 clinical trials in Stavanger, Norway across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Stavanger at a glance
131
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

131 trials in Stavanger

Open in trial search

Plasma cell myeloma

Not recruiting

Study on Early Treatment for Multiple Myeloma Relapse Using Carfilzomib, Bortezomib, Daratumumab, Lenalidomide, and Dexamethasone in Patients with MRD Negativity

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Oslo University Hospital HF

Duchenne muscular dystrophy

Not recruiting

Study on Eteplirsen for Patients with Duchenne Muscular Dystrophy with Deletion Mutations Amenable to Exon 51 Skipping

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Eteplirsen
  • Sponsor:Sarepta Therapeutics Inc.

Hidradenitis

Not recruiting

Study of lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lutikizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Enasidenib Mesilate
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Ovarian cancer

Not recruiting

Study of olaparib, durvalumab and UV1 combination as maintenance treatment for patients with recurrent ovarian cancer who do not have BRCA mutations

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Alrefimotide
  • Sponsor:Nordic Society Of Gynaecological Oncology Clinical Trial Unit

Malignant melanoma stage IV+1

Not recruiting

Study of Nivolumab and Relatlimab for Patients with Stage III-IV Melanoma After Surgery

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

K-ras gene mutation+2

Not recruiting

Study on Sotorasib for Patients with Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer and Comorbidities

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Sotorasib
  • Sponsor:Vestre Viken HF

Sjogren's syndrome

Not recruiting

Study on Hydroxychloroquine, Leflunomide, and Mycophenolate Mofetil for Patients with Primary Sjogren's Syndrome

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Leflunomide
  • Sponsor:Assistance Publique Hopitaux De Paris

Dementia Alzheimer's type

Not recruiting

Study on the Effectiveness and Safety of GSK4527226 in Patients with Early Alzheimer's Disease

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:Glaxosmithkline Research & Development Limited

Plasma cell myeloma

Not recruiting

Study on the Effectiveness of Talquetamab and Teclistamab in First-Line Treatment for Transplant-Eligible Multiple Myeloma Patients

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:North Estonia Medical Centre Foundation

Plasma cell myeloma

Not recruiting

Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Pfizer Inc.

Juvenile idiopathic arthritis

Not recruiting

Study on the Effectiveness of Triamcinolone Hexacetonide Injections for Juvenile Idiopathic Arthritis in Patients Starting TNF Inhibitor Treatment

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Triamcinolone Hexacetonide
  • Sponsor:Oslo University Hospital HF

Other cities in Norway

The busiest research cities in the country

All 54 cities in Norway

Clinical research in Stavanger

What the registry says about research in the country

01 Respiratory Medicine

Research focusing on respiratory tract infections and breathing disorders, including studies on chronic wet cough in children and innovative treatments for asthma prevention.

  • Antibiotic efficacy in pediatric respiratory conditions
  • Viral respiratory infections management
  • Wheezing and bronchiolitis treatments

Studies evaluating new therapeutic approaches for both acute and chronic respiratory conditions.

02 Oncology Research

Comprehensive cancer studies exploring treatments for various types including breast cancer, lung cancer, and rare cancers.

  • Targeted therapies for lung cancer
  • Precision medicine in rare cancers
  • Prostate cancer biomarker studies

Focus on personalized treatment approaches and innovative therapeutic combinations.

03 Cardiovascular Medicine

Investigations into stroke prevention and cardiovascular disease management, with emphasis on new therapeutic agents.

  • Atrial fibrillation treatments
  • Atherosclerotic disease prevention
  • Acute ischemic stroke interventions

Studies aimed at reducing cardiovascular events and improving patient outcomes.

Back to NorwayAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.